Merrimack Pharmaceuticals Closure: Impact on Shareholders

Merrimack Pharmaceuticals Announces Closure Following $225 Million FDA Approval Milestone

CAMBRIDGE, Mass. — In a significant development for the pharmaceutical industry, Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) has declared its intent to dissolve after receiving a milestone payment of $225 million. This substantial sum, awarded by Ipsen SA, comes after the U.S. Food and Drug Administration (FDA) greenlit Onivyde for the first-line treatment of metastatic pancreatic ductal adenocarcinoma.